Health-Related Quality of Life Among Young Adults with Multiple Sclerosis

2010 ◽  
Vol 12 (4) ◽  
pp. 190-199 ◽  
Author(s):  
Robert J. Buchanan ◽  
Chunfeng Huang ◽  
Michael Kaufman

Multiple sclerosis (MS) is an unpredictable disease that can have physical, psychological, and social impacts, reducing health-related quality of life (HRQOL). The objective of this study was to identify factors associated with HRQOL among young adults with MS. Survey data were collected from 100 people with MS aged 18 to 31 years, with 93 participants providing all data needed for analyses of our regression models. The survey cohort was recruited from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry (now the NARCOMS/Global Patient Registry). Multiple linear regression models were used to analyze the data, with the Physical Component Summary and the Mental Component Summary of the 8-item Short Form Health Status Survey serving as dependent variables. Independent variables were other survey responses, including demographic, disease, and treatment characteristics. The results indicated that full-time employment, relapsing-remitting course of MS, and satisfaction with access to MS-focused care were associated with better physical dimensions of HRQOL. Conversely, MS symptoms that interfered with daily life and perceptions of not having as good a social life as other people of comparable age were linked to poorer physical dimensions of HRQOL. Worsening MS symptoms, not having as good a social life as other people of comparable age, and seeing a mental health professional in the previous 12 months were associated with poorer mental dimensions of HRQOL. Our study highlights the association of MS-focused care with better physical dimensions of HRQOL among young adults with MS.

2021 ◽  
pp. 1-6
Author(s):  
Cihat Uzunköprü ◽  
Yesim Beckmann ◽  
Sabiha Türe

<b><i>Introduction:</i></b> The primary aim of the present study was to evaluate the long-term efficacy of fingolimod in patients with multiple sclerosis (MS); secondary aims were to describe the safety of fingolimod with the evaluation of treatment satisfaction and impact on the quality of life in real life. <b><i>Methods:</i></b> We collected clinical, demographical, neuroradiological, and treatment data, including pre- and posttreatment status health-related quality of life from 286 MS patients consecutively treated with fingolimod. Clinical assessment was based on the Expanded Disability Status Scale (EDSS), and quality of life assessment was performed with MS-related quality of life inventory (MSQOLI). The data were recorded at baseline and every 6 months for 2 years. <b><i>Results:</i></b> One hundred and fourteen males and 172 females were enrolled. The annualized relapse rate and EDSS showed a statistically significant reduction during the observation period (<i>p</i> &#x3c; 0.001). The patients also demonstrated substantial improvements in magnetic resonance imaging (MRI) outcomes (<i>p</i> &#x3c; 0.001). Health-related quality of life scores improved significantly between baseline and 24-month visit (<i>p</i> &#x3c; 0.001). No serious adverse events occurred. <b><i>Conclusion:</i></b> In our cohort, fingolimod treatment was associated with reduced relapse, MRI activity, and improved EDSS and MSQOLI scores. Additionally, fingolimod has been able to maintain its effectiveness over a considerable long period of treatment.


2013 ◽  
Vol 20 (2) ◽  
pp. 253-257 ◽  
Author(s):  
Mariko Kita ◽  
Robert J Fox ◽  
J Theodore Phillips ◽  
Michael Hutchinson ◽  
Eva Havrdova ◽  
...  

Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing–remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS.


Physiotherapy ◽  
2016 ◽  
Vol 102 ◽  
pp. e226-e227
Author(s):  
S.-J. Ryan ◽  
A. Marcar ◽  
P. Stone ◽  
K. Garikipati ◽  
R. Kuisma ◽  
...  

1995 ◽  
Vol 4 (3) ◽  
pp. 187-206 ◽  
Author(s):  
B. G. Vickrey ◽  
R. D. Hays ◽  
R. Harooni ◽  
L. W. Myers ◽  
G. W. Ellison

Sign in / Sign up

Export Citation Format

Share Document